BACKGROUND: The current US national stockpile of influenza H5 vaccine was produced using the antigen from the strain A/Vietnam/1203/2004 (a clade 1 H5 virus). Recent H5 disease has been caused by antigenically divergent H5 viruses, including A/Indonesia/05/2005 (a clade 2 H5 virus). METHODS: The influence of schedule on the antibody response to 2 doses of H5 vaccines (one a clade 1 hemagglutinin protein [HA] vaccine and one a clade 2 HA vaccine) containing 90 μg of antigen was evaluated in healthy adults 18-49 years of age. RESULTS: Two doses of vaccine were required to induce antibody titers ≥ 1:10 in most subjects. Accelerated schedules were immunogenic, and antibody developed after vaccinations on days 0 and 7, 0 and 14, and 0 and 28, with the day 0 and 7 schedule inducing lower titers than those induced with the other schedules. With mixed vaccine schedules of clade 1 followed by clade 2 vaccine administration, the first vaccination primed for a heterologous boost. The heterologous response was improved when the second vaccination was given 6 months after the first, compared with the response when the second vaccination was given after an interval of 1 month. CONCLUSIONS: An accelerated vaccine schedule of injections administered at days 0 and 14 was as immunogenic as a vaccine schedule of injections at days 0 and 28, but both schedules were inferior to a vaccine schedule of injections administered at 0 and 6 months for priming for heterologous vaccine boosting. Clinical Trial Registry Number: NCT00703053.
RCT Entities:
BACKGROUND: The current US national stockpile of influenza H5 vaccine was produced using the antigen from the strain A/Vietnam/1203/2004 (a clade 1 H5 virus). Recent H5 disease has been caused by antigenically divergent H5 viruses, including A/Indonesia/05/2005 (a clade 2 H5 virus). METHODS: The influence of schedule on the antibody response to 2 doses of H5 vaccines (one a clade 1 hemagglutinin protein [HA] vaccine and one a clade 2 HA vaccine) containing 90 μg of antigen was evaluated in healthy adults 18-49 years of age. RESULTS: Two doses of vaccine were required to induce antibody titers ≥ 1:10 in most subjects. Accelerated schedules were immunogenic, and antibody developed after vaccinations on days 0 and 7, 0 and 14, and 0 and 28, with the day 0 and 7 schedule inducing lower titers than those induced with the other schedules. With mixed vaccine schedules of clade 1 followed by clade 2 vaccine administration, the first vaccination primed for a heterologous boost. The heterologous response was improved when the second vaccination was given 6 months after the first, compared with the response when the second vaccination was given after an interval of 1 month. CONCLUSIONS: An accelerated vaccine schedule of injections administered at days 0 and 14 was as immunogenic as a vaccine schedule of injections at days 0 and 28, but both schedules were inferior to a vaccine schedule of injections administered at 0 and 6 months for priming for heterologous vaccine boosting. Clinical Trial Registry Number: NCT00703053.
Authors: J J Treanor; B E Wilkinson; F Masseoud; J Hu-Primmer; R Battaglia; D O'Brien; M Wolff; G Rabinovich; W Blackwelder; J M Katz Journal: Vaccine Date: 2001-02-08 Impact factor: 3.641
Authors: Iain Stephenson; Karl G Nicholson; Anthony Colegate; Audino Podda; John Wood; Ellen Ypma; Maria Zambon Journal: Vaccine Date: 2003-04-02 Impact factor: 3.641
Authors: Iain Stephenson; Roberto Bugarini; Karl G Nicholson; Audino Podda; John M Wood; Maria C Zambon; Jacqueline M Katz Journal: J Infect Dis Date: 2005-03-14 Impact factor: 5.226
Authors: T Rowe; R A Abernathy; J Hu-Primmer; W W Thompson; X Lu; W Lim; K Fukuda; N J Cox; J M Katz Journal: J Clin Microbiol Date: 1999-04 Impact factor: 5.948
Authors: Nega Ali Goji; Carrie Nolan; Heather Hill; Mark Wolff; Diana L Noah; Tracy B Williams; Thomas Rowe; John J Treanor Journal: J Infect Dis Date: 2008-09-01 Impact factor: 5.226
Authors: Tinh Hien Tran; Thanh Liem Nguyen; Thi Dung Nguyen; Thi San Luong; Phuong Mai Pham; van Vinh Chau Nguyen; Thi Suu Pham; Cong Dong Vo; Thi Quynh Mai Le; Thi Thi Ngo; Bach Khoa Dao; Phuc Phat Le; Thanh Truong Nguyen; Thuy Long Hoang; Viet Tung Cao; Truong Giang Le; Dac Tho Nguyen; Hong Nga Le; Kim Tien Nguyen; Hoang San Le; Van Tuan Le; Dolecek Christiane; Tan Thanh Tran; de Jong Menno; Constance Schultsz; Peter Cheng; Wilina Lim; Peter Horby; Jeremy Farrar Journal: N Engl J Med Date: 2004-02-25 Impact factor: 91.245
Authors: Katie L Winarski; Natalie J Thornburg; Yingchun Yu; Gopal Sapparapu; James E Crowe; Benjamin W Spiller Journal: Proc Natl Acad Sci U S A Date: 2015-07-13 Impact factor: 11.205
Authors: Xiangjie Sun; Jessica A Belser; Joanna A Pulit-Penaloza; Hannah M Creager; Zhu Guo; Stacie N Jefferson; Feng Liu; Ian A York; James Stevens; Taronna R Maines; Daniel B Jernigan; Jacqueline M Katz; Min Z Levine; Terrence M Tumpey Journal: Virology Date: 2017-05-26 Impact factor: 3.616
Authors: Jessica L Halliley; Surender Khurana; Florian Krammer; Theresa Fitzgerald; Elizabeth M Coyle; Ka Yan Chung; Steven F Baker; Hongmei Yang; Luis Martínez-Sobrido; John J Treanor; Kanta Subbarao; Hana Golding; David J Topham; Mark Y Sangster Journal: J Infect Dis Date: 2015-04-02 Impact factor: 5.226